Overview
- Nationwide plaintiffs and the Japanese government reached a settlement on January 15 in an appeal at the Fukuoka High Court.
- Eligibility for state compensation now extends to chronic hepatitis B patients who suffer repeated re-recurrence after infections linked to reused syringes in mass vaccinations.
- About 160 people with ongoing cases are expected to receive relief under the agreement.
- A 2021 Supreme Court ruling set the statute start at recurrence for recurrent-type patients, and the state had not applied that timing to re-recurrence cases until this settlement.
- Reports did not specify compensation amounts or outline implementation details for the expanded relief.